Concepedia

D-Y. Oh

DO

Statistics

Publications

3

Citations

90

H-Index

3

Active since

2022

Affiliations

Seoul National University Hospital(Current)

Tennessee Oncology

Sarah Cannon

Memorial Sloan Kettering Cancer Center

Seoul National University Bundang Hospital

D-Y. Oh is an author at Seoul National University Hospital specializing in pharmacology, oncology, and medicine.

Publications per year

2022–2025

3

Publications

3

460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers

Komal Jhaveri, Hyo S. Han, Efrat Dotan et al. · Annals of Oncology · 2022 · 54 citations · Full text

, , +17

78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

D-Y. Oh, A.R. He, S. Qin et al. · Annals of Oncology · 2022 · 26 citations

, , +9

LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma

J. Tabernero, S-E. Al-Batran, Zev A. Wainberg et al. · Annals of Oncology · 2025 · 10 citations

, , +9

1–3 of 3